Diagnostics CDMO Solutions

Diagnostics CDMO Solutions — MycoVista

Speed, reproducibility, and a documentation spine built for RUO → IVD.

Introduction: The Diagnostic Imperative

At MycoVista Diagnostics CDMO Solutions, we understand that diagnostics are not simply reagents in a vial — they are the frontline of healthcare decision-making. Every diagnostic enzyme, antigen, or antibody fragment contributes directly to the accuracy of test results, whether in point-of-care lateral flow assays, centralized molecular diagnostics, or next-generation sequencing platforms.

Unlike therapeutics, where timelines can stretch across years, diagnostic markets demand rapid scale-up, consistent reproducibility, and flawless documentation from day one. A single drift in enzyme activity, or a missing ISO 13485 record, can derail an entire supply chain.

MycoVista Biotech, From Sequence to supply chain

Our role is to eliminate those risks. At MycoVista, we combine fermentation-first expertise, precision purification, and ISO-aligned quality systems to manufacture diagnostic enzymes, proteins, and fragments at the speed and consistency your market requires. Our dual hubs in San Diego and Montréal provide mirrored quality and resilient supply, while our unified digital QMS (ALCOA+) ensures that every lot is audit-ready.

What MycoVista Diagnostics CDMO Solutions Provides

We manufacture:

  • Recombinant enzymes including Bst polymerases, reverse transcriptases, RNase inhibitors, and other critical amplification reagents.
  • Recombinant antigens & protein standards for serological assays and calibration.
  • Antibody fragments (Fabs, scFvs) for lateral flow and ELISA platforms.

Our Quality System delivers:

  • ISO 13485-aligned QC frameworks and batch documentation.
  • Endotoxin-controlled manufacturing, critical for assays where sensitivity can be compromised by contamination.
  • Lot-to-lot reproducibility tracked with statistical drift alerts using PAT and electronic batch records (eBMR).

Our Advantage:
Diagnostic developers face a dual challenge: the need for fast turnarounds and the assurance of clean, auditable paperwork. MycoVista solves both.

Sector Challenges & How We Solve Them

1. Speed to Market

Diagnostic companies often face compressed timelines — RUO kits must be delivered within weeks, and IVD products often require aggressive launches to capture regulatory windows or pandemic-driven demand.

  • Our solution: Phase-appropriate production pipelines with fast-turnaround microbial fermentation and standardized purification workflows. Pilot lots are ready in weeks, not months.
2. Reproducibility at Scale

Enzyme activity can drift subtly between production runs, leading to lot-to-lot inconsistency and unreliable assays.

  • Our solution: In-line PAT monitoring, DoE-driven process optimization, and statistical lot drift monitoring built into our digital QMS. Clients receive drift reports with every lot.
3. Regulatory Documentation

Diagnostics must flow seamlessly from RUO → IVD → regulatory filing, often under ISO 13485 and FDA QSR.

  • Our solution: Audit-ready documentation captured under ALCOA+ principles, harmonized across both hubs. Batch records are traceable, complete, contemporaneous, and legible for regulatory inspections.

Our Capabilities in Detail

Recombinant Enzyme Manufacturing

  • Expression in E. coli, Pichia, or Bacillus depending on enzyme complexity.
  • Rapid scale-up from pilot to GMP-like conditions.
  • Purification workflows: affinity, ion exchange, size exclusion.
  • QC release testing for activity, stability, purity, endotoxin.

Antigen & Protein Standards

  • Recombinant antigen design with native-like folding.
  • Purity and homogeneity validation by SEC-MALS and LC-MS peptide mapping.
  • Stability testing for long-term storage and kit deployment.
  • Reference standard preparation with full traceability.

Antibody Fragments

  • Engineered Fabs and scFvs for lateral flow devices.
  • Expression in microbial or mammalian systems.
  • DSP workflows tuned for fragment stability and binding activity.
  • QC for specificity, sensitivity, and reproducibility in assay formats.

Program Flow: From R&D to IVD

MycoVista Diagnostics CDMO Solutions applies a consistent, transparent workflow to every program:

  1. Technical Deep-Dive – Define enzyme/protein specifications, activity targets, and regulatory requirements.
  2. Proposal – Scope, cost, and timelines provided; iterated until aligned.
  3. QA Access – Optional pre-award QA audits for transparency.
  4. Onboarding (First 30 Days):
    • QTPP/CQA mapping.
    • Draft control strategy.
    • DoE plan for activity and stability optimization.
    • Gantt + FMEA for RUO to IVD scale.
  5. Design → Data – Execution of DoE, PAT-driven decisions, drift alerts, and weekly updates.
  6. Decision Gate – Advance only with validated processes that scale and withstand regulatory review.

Analytics First: The MycoVista Edge

Diagnostics are judged not only by yield, but by activity and reproducibility. Our analytics suite ensures no surprises:

  • Activity assays for enzyme kinetics.
  • Stability screens under multiple buffer/storage conditions.
  • Purity and homogeneity by SEC-MALS, LC-MS.
  • Endotoxin/bioburden control for sensitive assays.
  • Statistical drift analysis across production runs.

Every lot ships with a QC dossier that supports both RUO customers and regulatory reviewers.

Facilities & Scale

  • Microbial Systems: Bench → pilot → up to 50,000 L stainless for enzyme production.
  • Mammalian (optional): CHO/HEK for complex antibodies.
  • Fungal Systems: Pichia and Aspergillus for challenging proteins.
  • Cleanrooms: ISO 8/7, unidirectional flow, validated utilities.
  • Support suites: Media prep, QC labs, molecular analytics.

Case Examples

  • Polymerase for RT-LAMP assays: Pilot lot produced in 4 weeks, scaled to IVD-ready lots in 8 weeks, with QC packages aligned to ISO 13485.
  • Antigen for serological testing: Recombinant protein with validated glycan structure, reproducible across 6 lots, used as a reference standard in an FDA submission.
  • Antibody fragment for lateral flow: Microbial expression, DSP optimized for binding stability, reproducibility confirmed with drift alerts across production.

Why Teams Choose MycoVista Diagnostics CDMO Solutions

  • Speed: Pilot lots in weeks, not months.
  • Reproducibility: Drift monitoring and PAT ensure lot consistency.
  • Documentation: ISO 13485-aligned, inspection-grade from day one.
  • Dual-Hub Resilience: San Diego and Montréal provide mirrored supply and QA systems.
  • Analytics First: Activity, purity, stability locked in early.

Conclusion

Diagnostics demand speed, reproducibility, and audit-ready documentation. At MycoVista Diagnostics CDMO Solutions, we deliver all three, powered by microbial fermentation expertise, precision purification, and ISO-aligned quality. Whether you are developing a research-use enzyme, an IVD antigen, or a lateral flow antibody fragment, we provide the platform, the analytics, and the documentation to get you to market with confidence.

Contact us at info@mycovistabiotech.com today!